Actinogen buys Corticrine, pursues dementia treatment

Biotech firm Actinogen has signed an agreement to buy pharmaceutical company Corticrine for about $5.75 million, which focuses on the development of treatments for disease modification and prevention in Alzheimer’s dementia.